

A Functional Analysis of the Role of *IGF2* in *IDDM2*-Encoded Susceptibility to Type 1 Diabetes

Petros Vafiadis, Rosemarie Grabs, Cindy G. Goodyer, Eleanor Colle, and Constantin Polychronakos

Genetic studies have identified a number of loci demonstrating linkage to type 1 diabetes. One of the largest single contributors to genetic susceptibility, after the major histocompatibility complex, is the *IDDM2* locus, which maps to a nontranscribed variable number of tandem repeats (VNTR) minisatellite upstream of the insulin (*INS*) and insulin-like growth factor 2 (*IGF2*) genes. In a progression from population to functional studies, recent reports have shown that VNTR susceptibility alleles (class I) have different transcriptional effects on *INS* than protective VNTR alleles (class III) in thymus and pancreas, two tissues important in the pathogenesis of the disease. Similar VNTR transcriptional effects on *IGF2* have also been proposed as a mechanism by which the *IDDM2* locus confers susceptibility in addition to, or instead of, effects on *INS*. We evaluated this hypothesis by comparing *IGF2* expression levels from chromosomes with the protective class III alleles to those with class I alleles in tissues relevant to type 1 diabetes pathogenesis. In thymus, class III alleles were associated with an *IGF2* mRNA level of 4.7 ± 0.9 (mean \pm SE, arbitrary units, $n = 12$) compared with 4.7 ± 1.3 for class I alleles ($n = 17$). The same absence of a significant difference was found in pancreas, where class III alleles were associated with a level of 28.4 ± 4.2 ($n = 7$) and class I alleles with a level of 29.5 ± 5.2 ($n = 6$). There was a significant correlation between fetal age and *IGF2* in both tissues, but fetal ages were not different in the genotype groups compared. We therefore did not detect any significant difference in *IGF2* mRNA levels associated with the protective class of VNTR alleles as compared with the predisposing class. This is evidence against the hypotheses that have suggested *IGF2* is a mediator of *IDDM2*-encoded susceptibility and corroborates previous studies suggesting insulin is the gene involved. *Diabetes* 47:831–836, 1998

From the Endocrine Genetics Laboratory, McGill University–Montreal Children's Hospital Research Institute; Department of Pediatrics, Division of Endocrinology, McGill University, Montreal, Quebec, Canada.

Address correspondence and reprint requests to Constantin Polychronakos, Montreal Children's Hospital, 2300 Tupper St., Room E-316, Montreal, Quebec, Canada, H3H 1P3. E-mail: mc97@musica.mcgill.ca.

Received for publication 8 September 1997 and accepted in revised form 2 February 1998.

bp, base pair; PCR, polymerase chain reaction; Q-C-RT-PCR, quantitative competitive reverse transcription–polymerase chain reaction; VNTR, variable number of tandem repeats; UTR, untranslated region.

Type 1 diabetes is characterized by a breakdown in cellular immune tolerance to the insulin-producing pancreatic β -cells (1). It is a polygenic disorder, linked to several genetic loci (2,3). The *IDDM2* susceptibility locus maps to a variable number of tandem repeats (VNTR) minisatellite on 11p15.5, upstream of the insulin (*INS*) and insulin-like growth factor 2 (*IGF2*) genes (4–11). The individual repeat sequences are 14–15 base pairs (bp) long with the consensus sequence ACAGGGGT-GTGGGG (7,12–15). The VNTR alleles fall mostly into two common size classes (10,16). Class I alleles (26–63 repeats) are predisposing to type 1 diabetes, while class III alleles (140–210 repeats) have a dominant protective effect.

The molecular and pathophysiologic mechanisms by which *IDDM2* determines risk are not known. Since the VNTR is not transcribed, its allelic forms must be exercising their effect by regulating gene transcription. We have, therefore, begun a systematic search in pancreas and thymus, tissues known to be of importance in the pathogenesis of type 1 diabetes, for VNTR allelic effects on mRNA levels of the nearby *INS* and *IGF2* genes. The products of these genes have well-characterized functions that suggest likely hypotheses for their contribution to *IDDM2*-encoded susceptibility.

The insulin gene is a target of tissue-specific VNTR transcriptional effects, and its product is the only known β -cell-specific autoantigen in type 1 diabetes. In vitro, two studies have shown that class III VNTR alleles are associated with higher gene expression than class I alleles in β -cells (17,18), while a third reports association of class III alleles with lower expression (19). The reason for the discrepancy is not clear. Studies performed in vivo on human pancreas confirm that class III VNTR alleles are associated with a statistically significant but marginal decrease in insulin expression (10,20,21). Insulin is also expressed in human thymus (22,23), with a marked VNTR allele effect on *INS* transcription levels. Most class III VNTR alleles are associated with two- to threefold higher levels of insulin expression than class I alleles (22,23). We and others have proposed that alleles that enhance thymic insulin expression will help induce better immune tolerance to the autoantigen. Such a gain of function could explain the dominant protective effect of the class III VNTR alleles.

VNTR allelic effects on *INS* do not exclude the possibility that other genes are involved in *IDDM2*-encoded susceptibility instead of, or in addition to, *INS*. The *IGF2* gene is transcribed from four promoters located 4–27 kilobases downstream of the VNTR, a distance compatible with transcriptional control. VNTR transcriptional effects on

IGF2 expression have been shown in human placenta (24), indicating the potential for similar transcriptional effects to occur in other tissues.

In most tissues, *IGF2* is expressed only from the paternally inherited copy (25,26). The maternally inherited copy is transcriptionally silent. This is the phenomenon known as genomic imprinting (27). Therefore, only the paternal VNTR alleles can act on *IGF2* expression. This may explain the parent-of-origin effects seen in some populations for transmission of VNTR alleles (5,10,21,28,29).

There are also biological roles of IGF-II that suggest possible primary functions in the pathogenesis of type 1 diabetes (30). IGF-II is a ubiquitously expressed mitogenic peptide with important autocrine/paracrine signaling actions (31). Regulation of local IGF-II levels may thus modulate aspects of the process leading to type 1 diabetes. In pancreas, alleles associated with higher *IGF2* expression may enhance paracrine signaling to T-cells and thus promote progression of the immune assault on β -cells. In transgenic mice, overexpression of *IGF2* in thymus resulted in decreased thymocyte apoptosis (32,33) via an autocrine/paracrine mechanism. Alleles that increase *IGF2* expression in thymus would, therefore, increase the probability that potentially autoreactive thymocytes will reach maturity. Alternatively, it has been proposed that thymic IGF-II may act as a selecting peptide against insulin-reactive T-cells (34,35), given its high homology to proinsulin.

In this study, we directly address these hypotheses by comparing *IGF2* transcription levels from chromosomes with paternal class III VNTR alleles to those with paternal class I alleles in human fetal thymus and pancreas.

RESEARCH DESIGN AND METHODS

Samples. Human fetal pancreas and thymus samples, between 12.3 and 22 weeks' fetal age, and maternal blood were obtained at the time of pregnancy termination with written maternal consent and approval by the Institutional Review Boards of the Maisonneuve-Rosemont and Montreal Children's Hospitals. Tissues were immediately frozen, and nucleic acids were extracted using phenol-chloroform.

Genotyping. All samples were genotyped for VNTR status by polymerase chain reaction (PCR) as previously described (20,22). Individual class I alleles differing in length by a single repeat could be resolved by PAGE and designated by a three-digit number representing size in mobility units, following previously established terminology (10). DNA from maternal blood was also typed for VNTR. Stable inheritance of a single maternal VNTR allele was confirmed in most fetal samples studied, and the other allele was designated the paternal VNTR allele.

Quantitation of *IGF2* in thymus and pancreas. *IGF2* expression in thymus (30) and pancreas (20) is exclusively from the paternally inherited allele. Therefore, steady-state mRNA levels of samples with a paternal class III VNTR allele were compared with those with a paternal class I allele, using a quantitative competitive reverse transcription-PCR (Q-C-RT-PCR) method. The RNA concentration of each sample was determined by optical density, and an equal amount of each was reverse transcribed to cDNA using random hexamer primers and Superscript RT (Gibco). Parallel samples to which Superscript RT was not added were assayed by PCR to confirm the absence of genomic DNA contamination or PCR carryover. An equal volume of cDNA from every sample was then added to each of three different amounts of an *IGF2* PCR competitor and amplified by a previously described PCR method (36) for a 236-bp segment of exon 9 of *IGF2* in the 3' untranslated region (UTR). This segment is shared by transcripts from all four *IGF2* promoters. The competitor sequence is identical to the endogenous 236-bp segment except for a 39-bp internal deletion made by PCR-based *in vitro* mutagenesis (37). Because both templates are amplified in the same PCR tube with the same PCR primers, the efficiency of amplification of the two templates is equal. The ratio of PCR product obtained for each template is thus proportional to the ratio in the starting template. The PCR products were labeled internally with 32 P-dATP, resolved by PAGE, and quantitated using a phosphorimager (Fuji) to obtain three ratios for each sample representing the amount of endogenous *IGF2* relative to a known amount of *IGF2* competitor.

To confirm equal loading, the amount of starting RNA in each RT reaction described above was determined by Q-C-RT-PCR on the cyclophilin house-keeping gene, which can be used as an indicator for total amount of RNA, using commercially available primers and an RNA cyclophilin PCR-competitor construct, as per the manufacturer's instructions (QuantumRNA Module; Ambion). The RNA cyclophilin competitor is identical to the endogenous cyclophilin sequence, except for a 25-bp internal deletion. An equal number of competitor copies was added to each RT reaction and amplified along with the endogenous cyclophilin cDNA. The PCR products were resolved using PAGE, and the bands corresponding to endogenous cyclophilin and cyclophilin competitor were quantitated to obtain a ratio of endogenous to competitor.

The *IGF2* ratios for each sample were normalized for amount of starting RNA, using the cyclophilin measurements as an indicator of total RNA content, and averaged. This mean represents the amount of *IGF2* mRNA for a set amount of total RNA. The calculations for comparing *IGF2* mRNA levels across samples are as follows:

- (endogenous *IGF2*/competitor *IGF2*) = amount of endogenous *IGF2* transcripts relative to a known amount of PCR competitor ($n = 3$ per sample);
- $1/(\text{endogenous cyclophilin}/\text{competitor cyclophilin}) = \text{normalizing factor for amount of RNA in each sample } (n = 1 \text{ per sample});$
- (normalizing factor) \times (endogenous *IGF2*/competitor *IGF2*) = normalized ratio for the amount of endogenous *IGF2* relative to a known amount of competitor for a set amount of total RNA ($n = 3$ per sample);
- (normalized ratio) \times (moles of competitor added per reaction) = amount of *IGF2* mRNA ($n = 3$ per sample); and
- for each sample, average the amount of *IGF2* mRNA measured at each concentration of competitor assayed ($n = 3$ per sample).

Establishment of the Q-C-RT-PCR method. To verify that the relative amount of endogenous and competitor PCR product is proportional to the amount of each starting template and to determine the appropriate competitor concentrations to be used, a small number of samples were titrated against varying concentrations of competitor. For the *IGF2* mRNA quantitation, various amounts of competitor (1.25, 2.5, 5, 10, 20, 40, 50, 80, 100, 125, 200, and 400 amol) were added to an equal amount of cDNA from the same pancreas or thymus sample and amplified by PCR. This was repeated several times for each tissue using various numbers of PCR cycles. The competitor concentration at which the ratio of endogenous to competitor product was approximately 1, the next higher and the next lower concentrations were chosen to assay each sample in triplicate competitor concentrations. Similarly for cyclophilin, a known amount of competitor, ranging from 1×10^6 to 1×10^{10} copies, was added to 5 reverse transcription reactions, each with the same amount of starting RNA from the same pancreas or thymus sample. The concentration of competitor at which the ratio of endogenous to competitor product was closest to 1 was chosen to assay all samples.

RESULTS

Establishment of the Q-C-RT-PCR. For competitive RT-PCR to be quantitative, the ratio of endogenous to competitor PCR product must be proportional to the ratio in the starting template. Proportional amplification of the two templates was verified by titrating an equal amount of total RNA with varying amounts of competitor. For the cyclophilin Q-C-RT-PCR, the ratio of endogenous cyclophilin to copies of cyclophilin competitor added was shown to correlate with the proportion of each starting template with addition of between 1×10^8 and 1×10^{10} copies of competitor (pancreas $R^2 = 0.9931$, thymus $R^2 = 0.9951$) (Fig. 1); lower concentrations resulted in the endogenous transcripts completely outcompeting the competitor. An amount of 5×10^9 copies of cyclophilin competitor was added to each sample assayed because this was the concentration at which the endogenous to competitor ratio was near 1, indicating an approximately equal starting concentration of the two templates. The endogenous to competitor cyclophilin ratios obtained using a single competitor concentration covered a very tight range of values between the samples assayed (thymus: 0.4–2.6, with 76% of samples between 0.4 and 1.5; pancreas: 0.5–2.5, with 85% of samples between 0.5 and 1.5), indicating that the level of cyclophilin expression as a percentage of total RNA does not




FIG. 1. An identical amount of endogenous template was co-amplified with varying amounts of PCR competitor to confirm that the endogenous and competitor templates for (A) cyclophilin in pancreas, (B) cyclophilin in thymus, (C) *IGF2* in pancreas, and (D) *IGF2* in thymus were amplified with equal efficiency and, thus, that the relative amount of final PCR product is proportional to the relative amount of starting template. The results using 22 PCR cycles are shown.

vary greatly between individuals with fetal age between 12.3 and 22 weeks.

Similarly for the *IGF2* Q-C-RT-PCR, an equal amount of total RNA was titrated with concentrations of *IGF2* competitor by adding between 1.25 and 400 amol for both thymus and pancreas, with 18, 20, 22, 24, and 26 PCR cycles. The ratio of endogenous to competitor PCR product correlated with the proportion of starting template, indicating that the two templates are amplified with equal efficiency, regardless of cycle number (pancreas R^2 between 0.9137 and 0.9704; thymus R^2 between 0.9605 and 0.9779) (Fig. 1). While the absolute intensity of PCR product varied with the number of cycles, the ratio of endogenous to competitor product was not significantly affected. We thus chose to use 22 PCR cycles for all samples assayed because this was the minimal number of cycles at which strong bands were consistently attained. These experiments also establish the precision of the method, which was able to detect changes in competitor concentrations of less than twofold. All samples were assayed in triplicate by addition of 10, 20, or 40 amol of competitor.

***IGF2* expression levels in pancreas.** In pancreas, only the paternal *IGF2* gene copy is expressed (20). To compare the effects of class III VNTR alleles with class I alleles on *IGF2* expression level, we identified seven pancreas samples with a paternal class III VNTR allele and six with a paternal class I VNTR allele. The average *IGF2* mRNA level expressed from paternal chromosomes with a class III VNTR was 28.4 ± 4.2




FIG. 2. Representative autoradiographs of the *IGF2* quantitation assays, carried out in triplicate using 10, 20, or 40 amol of *IGF2* PCR competitor, are shown for two samples of human fetal pancreas (A) and thymus (B). The upper band (E) is the 236-bp endogenous *IGF2* RT-PCR product, and the lower band (C) corresponds to the 187-bp *IGF2* competitor product. C: The correlation of fetal age (weeks) with *IGF2* expression level for human fetal pancreas with a paternal class I VNTR allele (●), pancreas with a paternal class III allele (○), human fetal thymus with a paternal class I allele (■), and thymus with a paternal class III allele (□). The *IGF2* expression level for each sample is taken as the mean of measurements made using 10, 20, and 40 amol of *IGF2* competitor (Tables 1 and 2). Class I and III alleles are not associated with significantly different *IGF2* mRNA levels. There is a significant negative correlation of fetal age with *IGF2* mRNA level in both pancreas ($R = 0.6646$, $P < 0.0086$) and thymus ($R = 0.4700$, $P < 0.005$), independent of VNTR class.

(mean \pm SE, arbitrary units), compared with 29.5 ± 5.2 from paternal chromosomes with a class I VNTR, as determined by Q-C-RT-PCR (NS) (Table 1, Fig. 2A). Replication among the three competitor concentrations at which each sample was assayed was very good (mean coefficient of variation 0.1 [range 0.03–0.23]) (Table 1). There was a significant negative correlation of *IGF2* levels with fetal age ($R = 0.6646$, $P < 0.0086$, $n = 13$), but fetal ages were not different between the class I (median fetal age 15.4 weeks [13.8–21]) and class III (median fetal age 17 weeks [13.8–19]) groups (Table 1, Fig. 2C). These results demonstrate the absence of a significant VNTR allele effect on *IGF2* expression in pancreas.

***IGF2* expression levels in thymus.** As in pancreas, *IGF2* is imprinted in the thymus, resulting in exclusive expression from the paternal gene copy (30). Unlike insulin, which is expressed only in a rare subset of thymus cells (38), *IGF2* is ubiquitously expressed. To determine if there are VNTR allele effects on *IGF2* expression in thymus, *IGF2* mRNA levels were quantitated in 12 samples with a paternal class III VNTR allele and in 17 with a paternal class I VNTR allele. The

TABLE 1
IGF2 mRNA Q-C-RT-PCR results in human fetal pancreas

Maternal genotype	Fetal genotype	Paternal VNTR	Fetal age (weeks)	IGF2 mRNA level (amol)		
				10	20	40
683/683	683/728	728	21.0	13.6	11.3	11.0
NA	655/742	I	17.0	19.3	19.7	18.3
800/III	814/III	814	15.0	26.3	24.3	25.2
828/843	655/843	655	15.0	33.6	37.0	30.4
NA	669/828	I	13.8	42.2	36.1	38.7
669/III	814/III	814	15.8	58.1	43.9	35.3
728/814	814/III	III	16.0	18.6	14.0	12.8
756/770	756/III	III	17.0	24.5	17.4	19.8
655/828	828/III	III	18.0	24.1	15.6	28.0
698/756	756/III	III	17.0	24.8	33.0	28.5
843/843	843/III	III	16.0	33.8	27.1	29.2
800/976	976/III	III	19.0	34.9	30.1	31.0
786/III*	786/III*	III	13.8	48.5	49.2	51.7

The maternal genotype, fetal genotype, paternally inherited VNTR allele, and the fetal age of each sample are shown with the corresponding IGF2 mRNA levels obtained using three different competitor concentrations, in arbitrary units, after correcting for the amount of starting RNA and amount of competitor. Class I alleles are represented either by a three-digit number representing size in mobility units (10) or by an "I" when the size of the paternal allele could not be determined. *The maternal and fetal class III alleles were distinguishable by size. NA, not available.

average IGF2 mRNA level associated with the class III VNTR alleles was 4.7 ± 0.9 , compared with 4.7 ± 1.3 in those associated with the class I alleles (NS) (Table 2, Fig. 2B). Replication of the quantitated IGF2 level was very good among the three competitor concentrations used (mean coefficient of variation 0.24 [0.04–0.54]) (Table 2). There was a significant negative correlation of IGF2 levels with fetal age ($R = 0.4700$, $P < 0.005$, $n = 29$), but fetal ages were not different between the class I (median fetal age 15.8 weeks [12.3–22]) and class III (median fetal age 15.8 weeks [12.3–19]) groups (Table 2, Fig. 2C). Clearly there is no significant VNTR allele effect on IGF2 transcription in thymus.

DISCUSSION

The *IDDM2* locus is the only type 1 diabetes susceptibility locus that has been mapped to a specific genetic element besides *IDDM1*. This has permitted a functional analysis of the physiologic mechanism(s) by which *IDDM2* contributes to disease susceptibility. One such mechanism may be the tissue-specific modulation of *INS* expression in the thymus by VNTR alleles (22,23). A non-mutually exclusive hypothesis is that *IDDM2*-encoded susceptibility is mediated through IGF2 (30,34). To directly test this hypothesis, we compared IGF2 expression levels in vivo from chromosomes with a class III VNTR allele to those with a class I allele. There were no significant differences in IGF2 mRNA levels between the predisposing and protective classes of VNTR alleles in either pancreas or thymus. Small effects of VNTR class on IGF2 expression have been described in placenta (24). Thus, as with insulin, the effects of VNTR alleles on IGF2 expression are tissue specific.

Functionally, IGF2 has been considered a candidate for the *IDDM2* effect because of its well-characterized properties as a mitogenic peptide (30), with important autocrine/paracrine effects on thymus, lymphocytes, and pancreas (31–33). Its candidacy would also be supported by its potential role as a selecting peptide in the thymus, which

would promote tolerance to proinsulin, to which it has a high homology (34,35). The absence of differential VNTR allele effects on IGF2 expression in thymus and pancreas argues strongly against these considerations.

The preferential transmission of VNTR-susceptibility alleles at *IDDM2* from fathers to diabetic offspring has been described in some populations (5,10,21,28,29), but not in others (10,11,21,39). The absence of a differential effect between VNTR class I and III alleles on expression of the imprinted IGF2 gene suggests that if there is a parental effect in transmission of VNTR alleles, it is not mediated through IGF2. However, the parental effect may be mediated through the insulin gene, which shows polymorphic silencing of insulin transcription from chromosomes with a class III VNTR in thymus (22,23). This may represent allele-specific genomic imprinting where insulin transcription is silenced only when located *cis* to specific class III alleles and transmitted from a parent of a specific sex, resulting in a parent-of-origin effect.

Our analysis has assumed that the VNTR acts in *cis*, but it is conceivable that it may also modulate IGF2 transcription in *trans*. Action in *trans* by nontranscribed sequences would require postulating an unknown mechanism, as opposed to the well-known effect of enhancers in *cis*. Physical association of the two copies of the imprinted Prader-Willi locus on 15q12 has been reported, which might suggest such a mechanism (40). Even more intriguing, statistical evidence has recently been presented that the VNTR may act in *trans* in the paternal germ line (41). Paternally inherited 814 class I alleles do not predispose to type 1 diabetes when the untransmitted paternal allele is a class III, but they are as predisposing as all other class I alleles when the untransmitted allele is a class I. No evidence of such *trans* effects was found for other specific class I alleles. However, this phenomenon does not have a large effect on *IDDM2*-encoded susceptibility because only about 5% of individuals inherit an 814 allele from an 814/III father. It is therefore

TABLE 2
IGF2 mRNA Q-C-RT-PCR results in human fetal thymus

Maternal genotype	Fetal genotype	Paternal VNTR	Fetal age (weeks)	<i>IGF2</i> mRNA level (amol)		
				10	20	40
683/683	683/728	728	21.0	1.1	1.1	1.6
NA	786/814	I	22.0	1.4	1.5	3.0
814/814	814/814	814	14.5	1.3	1.6	2.7
814/III	641/814	641	20.0	1.4	1.8	2.9
742/814	786/814	786	15.5	1.7	2.1	3.1
828/843	655/843	655	15.0	1.6	2.2	3.0
800/800	800/800	800	14.0	1.8	2.3	2.8
669/III	814/III	814	15.8	2.1	2.0	3.2
NA	800/843	I	17.0	1.7	2.4	3.4
NA	800/828	I	22.0	4.6	5.1	—
NA	786/843	I	15.5	5.2	5.1	4.7
814/814	728/814	728	17.0	3.2	5.2	6.8
NA	683/770	I	17.0	4.0	6.2	6.1
NA	714/786	I	14.5	5.6	5.8	5.0
NA	786/843	I	15.8	4.0	6.9	—
NA	641/843	I	18.0	4.1	7.0	6.1
NA	669/843	I	12.3	17.9	31.4	24.1
814/828	828/III	III	14.8	1.3	1.8	1.8
698/756	756/III	III	17.0	1.0	1.4	2.4
669/814	669/III	III	15.3	1.4	1.9	3.8
655/828	828/III	III	18	1.7	2.3	3.3
728/814	814/III	III	16.0	2.2	2.5	3.0
756/770	756/III	III	17.0	1.9	2.6	3.6
800/976	976/III	III	19.0	1.9	2.1	5.7
786/III	III/III	III	16.0	4.7	6.2	6.8
III/III	III/III	III	15.7	7.1	7.6	6.7
786/III*	786/III*	III	13.8	5.8	7.1	11.2
756/756	756/III	III	15.0	7.1	10.6	—
843/III	III/III	III	12.3	9.1	7.8	15.3

The maternal genotype, fetal genotype, paternally inherited VNTR allele, and the fetal age of each sample are shown with the corresponding *IGF2* mRNA levels obtained using three different competitor concentrations, in arbitrary units, after correcting for the amount of starting RNA and amount of competitor. Class I alleles are represented either by a three-digit number representing size in mobility units (10) or by an "I" when the size of the paternal allele could not be determined. *The maternal and fetal class III alleles were distinguishable by size. NA, not available.

unlikely that *trans* effects are obscuring a VNTR allelic effect on *IGF2* expression in this study.

Our results do not entirely eliminate *IGF2* as the gene involved in *IDDM2*. The VNTR may have tissue-specific transcriptional effects on organs other than thymus and pancreas that are involved in the pathogenesis of diabetes in less obvious ways. These results are important, however, for the most efficient planning of future research on the *IDDM2* locus, which must now focus on the insulin gene.

ACKNOWLEDGMENTS

This work was supported by the Juvenile Diabetes Foundation International.

We would like to thank Dr. Yves Lefebvre for help in obtaining the fetal tissues and Dr. Robert D. Barnes for reviewing the manuscript.

REFERENCES

- Bach JF: Insulin-dependent diabetes mellitus as an autoimmune disease. *Endocr Rev* 15:516–542, 1994
- Todd JA, Farrall M: Panning for gold: genome-wide scanning for linkage in type 1 diabetes. *Hum Mol Genet* 5 Spec No:1443–1448, 1996
- Field LL, Tobias R: Unravelling a complex trait: the genetics of insulin-dependent diabetes mellitus. *Clin Invest Med* 20:41–49, 1997
- Bell GI, Horita S, Karam JH: A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. *Diabetes* 33:176–183, 1984
- Julier C, Hyer RN, Davies J, Merlin F, Soularue P, Briant L, Cathelineau G, Deschamps I, Rotter JI, Froguel P, Boitard C, Bell JI, Lathrop GM: Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. *Nature* 354:155–159, 1991
- Lucassen AM, Julier C, Beressi JP, Boitard C, Froguel P, Lathrop M, Bell JI: Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. *Nat Genet* 4:305–310, 1993
- Owerbach D, Gabbay KH: Localization of a type I diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. *Diabetes* 42:1708–1714, 1993
- Julier C, Lucassen A, Villiedieu P, Delepine M, Levy-Marchal C, Danze PM, Bianchi F, Boitard C, Froguel P, Bell J, Lathrop GM: Multiple DNA variant association analysis: application to the insulin gene region in type I diabetes. *Am J Hum Genet* 55:1247–1254, 1994
- Undlien DE, Bennett ST, Todd JA, Akselsen HE, Ikaheimo I, Reijonen H, Knip M, Thorsby E, Ronningen KS: Insulin gene region-encoded susceptibility to IDDM maps upstream of the insulin gene. *Diabetes* 44:620–625, 1995
- Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, Nerup J, Bouzekri N, Cambon-Thomsen A, Ronningen KS, Barnett AH, Bain SC, Todd JA: Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem

- repeat variation at the insulin gene minisatellite locus. *Nat Genet* 9:284–292, 1995
11. Bennett ST, Todd JA: Human type 1 diabetes and the insulin gene: principles of mapping polygenes. *Annu Rev Genet* 30:343–370, 1996
 12. Bell GI, Selby MJ, Rutter WJ: The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. *Nature* 295:31–35, 1982
 13. Ullrich A, Dull TJ, Gray A, Philips JA III, Peter S: Variation in the sequence and modification state of the human insulin gene flanking regions. *Nucleic Acids Res* 10:2225–2240, 1982
 14. Owerbach D, Aagaard L: Analysis of a 1963-bp polymorphic region flanking the human insulin gene. *Gene* 32:475–479, 1984
 15. Rotwein P, Yokoyama S, Didier DK, Chirgwin JM: Genetic analysis of the hypervariable region flanking the human insulin gene. *Am J Hum Genet* 39:291–299, 1986
 16. Bell GI, Karam JH, Rutter WJ: Polymorphic DNA region adjacent to the 5' end of the human insulin gene. *Proc Natl Acad Sci USA* 78:5759–5763, 1981
 17. Lucassen AN, Sreaton GR, Julier C, Elliott TJ, Lathrop M, Bell GI: Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. *Hum Mol Gen* 4:501–506, 1995
 18. Owerbach D, Gabbay KH: The search for IDDM susceptibility genes: the next generation. *Diabetes* 45:544–551, 1996
 19. Kennedy GC, German MS, Rutter WJ: The minisatellite in the diabetes susceptibility locus *IDDM2* regulates insulin transcription. *Nat Genet* 9:293–298, 1995
 20. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C: Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. *J Autoimmun* 9:397–403, 1996
 21. Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, Todd JA: IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. *J Autoimmun* 9:415–421, 1996
 22. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C: Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. *Nat Genet* 15:289–292, 1997
 23. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD: The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. *Nat Genet* 15:293–297, 1997
 24. Giannoukakis N, Vafiadis P, Polychronakos C, Paquette J, Deal C: Association between IGF2 expression and VNTR class at the INS 5' VNTR in human placenta (Abstract P1-520). *10th International Congress of Endocrinology*. San Francisco, CA, The Endocrine Society Press, 1996, p. 264
 25. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C: Parental genomic imprinting of the human IGF2 gene. *Nat Genet* 4:98–101, 1993
 26. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, Tohonen V, Hedborg F, Schofield P, Flam F, Ekstrom TJ: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. *Nat Genet* 4:94–97, 1993
 27. Polychronakos C: Parental imprinting of the genes for IGF-II and its receptor. In *Current Directions in IGF Research*. LeRoith D, Raizada MK, Eds. New York, Plenum, 1994, p. 189–203
 28. Bui MM, Luo DF, She JY, Maclaren NK, Muir A, Thomson G, She JX: Paternally transmitted IDDM2 influences diabetes susceptibility despite biallelic expression of the insulin gene in human pancreas. *J Autoimmun* 9:97–103, 1996
 29. Polychronakos C, Kukuvtis A, Giannoukakis N, Colle E: Parental imprinting effect at the INS-IGF2 diabetes susceptibility locus. *Diabetologia* 38:715–719, 1995
 30. Polychronakos C, Giannoukakis N, Deal CL: Imprinting of IGF2, insulin-dependent diabetes, immune function, and apoptosis: a hypothesis. *Dev Genet* 17:253–262, 1995
 31. Ward A, Bates P, Fisher R, Richardson L, Graham CF: Disproportionate growth in mice with Igf-2 transgenes. *Proc Natl Acad Sci USA* 91:10365–10369, 1994
 32. van Buul-Offers SC, de Haan K, Reijnen-Gresnigt MG, Meisma D, Jansen M, Oei SL, Bonte EJ, Sussenbach JS, Van den Brande JL: Overexpression of human insulin-like growth factor-II in transgenic mice causes increased growth of the thymus. *J Endocrinol* 144:491–502, 1995
 33. Kooijman R, van Buul-Offers SC, Scholtens LE, Schuurman HJ, Van den Brande LJ, Zegers BJ: T cell development in insulin-like growth factor-II transgenic mice. *J Immunol* 154:5736–5745, 1995
 34. Geenen V, Achour I, Robert F, Vandersmissen E, Sodoyez JC, Defresne MP, Boniver J, Lefebvre PJ, Franchimont P: Evidence that insulin-like growth factor 2 (IGF2) is the dominant thymic peptide of the insulin superfamily. *Thymus* 21:115–127, 1993
 35. Martens H, Goxe B, Geenen V: The thymic repertoire of neuroendocrine self-antigens: physiological implications in T-cell life and death. *Immunol Today* 17:312–317, 1996
 36. Tadokoro K, Fujii H, Inoue T, Yamada M: Polymerase chain reaction (PCR) for detection of Apal polymorphism at the insulin like growth factor II gene (IGF2). *Nucleic Acids Res* 19:6967, 1991
 37. Forster E: An improved general method to generate internal standards for competitive PCR. *Biotechniques* 16:18–20, 1994
 38. Smith KM, Olson DC, Hirose R, Hanahan D: Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. *Int Immunol* 9:1355–1365, 1997
 39. Bain SC, Prins JB, Hearne CM, Rodrigues NR, Rowe BR, Pritchard LE, Richie RJ, Hall JR, Undlien DE, Ronningen KS, Dunger DB, Barnett AH, Todd JA: Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals. *Nat Genet* 2:212–215, 1992
 40. LaSalle JM, Lalande M: Homologous association of oppositely imprinted chromosomal domains. *Science* 272:725–728, 1996
 41. Bennett ST, Wilson AJ, Esposito L, Bouzekri N, Undlien DE, Cucca F, Nistico L, Buzzetti R, the IMDIAB Group, Bosi E, Pociot F, Nerup J, Cambon-Thomson A, Pugliese A, Shield JPH, McKinney PA, Bain SC, Polychronakos C, Todd JA: Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. *Nat Genet* 17:350–352, 1997